Full history for every metric is available with a Kvantra account
VYNE Therapeutics Inc. (VYNE)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 21 | 1 | 0 | 0 | 1 | 1 | 1 |
| Operating profit | $m | -30 | -47 | |||||
| Net profit | $m | -256 | -73 | -23 | -28 | -40 | -26 | -42 |
| EPS reported | $ | -31.00 | -637.0 | |||||
| Operating cashflow per share | $ | -38.73 | -395.9 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -38.73 | -395.9 | |||||
| Free cash flow | $m | -33 | -17 | |||||
| Net debt | $m | -29 | -0 | |||||
| Book value equity | $m | 28 | - | |||||
| Book value per share | $ | 32.46 | - | |||||
| Number of shares | m | 0.86 | 0.04 | |||||
| DPS (TTM paid) | $ | 0.00 | 20.12 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.89 | 43.99 | |||||
| P/S LTM | x | 43.53 | 19.97 | |||||
| P/FCF LTM | x | -0.75 | -1.13 | |||||
| EV/EBITDA LTM | x | -0.03 | -0.42 | |||||
| EV/Sales LTM | x | 1.38 | 19.94 | |||||
| Earnings Yield LTM | % | -106.73% | -3453.7% | |||||
| FCF Yield | % | -133.49% | -88.80% | |||||
| Quality | ||||||||
| ROE | % | -95.38% | -199.65% | |||||
| ROIC | % | -107.15% | -159961.5% | |||||
| Operating margin | % | -5219.1% | -4877.1% | |||||
| Gross margin | % | 95.96% | 99.37% | |||||
| FCF/Sales | % | -5811.2% | -1773.1% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +13.77% | +100.63% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 50.94% | |||||
| Dividend Growth | % | 0.00% | - | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.90 | 0.00 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -116.90% | -0.15% | |||||
| Net debt/Equity | x | -1.04 | - | |||||
| Gross debt/equity | x | 0.00 | - | |||||
Company overview
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free